Showing 1261-1270 of 1319 results for "".
- AAN Guidelines for Diabetic Neuropathy Updatedhttps://practicalneurology.com/news/aan-guidelines-for-diabetic-neuropathy-updated/2469788/The American Academy of Neurology (AAN) has updated the 2011 AAN guideline on the treatment of painful diabetic neuropathy. There are many oral and topical medications that are effective in reducing nerve pain listed in the guideline. The guideline recommends treatments
- Trofinetide Treatment of Rett Syndrome Provides Clinician- and Caregiver-Rated Improvementhttps://practicalneurology.com/news/trofinetide-treatment-of-rett-syndrome-provides-clinician-and-caregiver-rated-improvement/2469776/A phase 3 study that evaluated the efficacy and safety of the investigational drug achieved positive topline results. The 12-week, placebo-controlled study demonstrated a statistically significant improvement in for both coprimary endpoints. In the LAVENDER study (
- Valbenazine Reduced Chorea Associated With Huntington Diseasehttps://practicalneurology.com/news/valbenazine-reduced-chorea-associated-with-huntington-disease/2469775/In a phase 3 study (NCT04102579), participants with Huntington disease (HD) treated with valbenazine (Ingrezza; Neurocrine Biosciences, San Diego, CA) had a reduction in chorea severity. Chorea re
- Phase 3 Study of Tolperisone for Muscle Spasms Completes Enrollmenthttps://practicalneurology.com/news/phase-3-study-of-tolperisone-for-muscle-spasms-completes-enrollment/2469759/Enrollment of 1,000 participants is complete for the phase 3 RESUME-1 study (NCT04671082) of tolperisone (Mydocalm; Neurana Pharmaceuticals, San Diego, CA) for muscle spasms associated with acute,
- Phase 3 Valbenazine for Chorea in Huntington Disease Completes Enrollmenthttps://practicalneurology.com/news/phase-3-valbenazine-for-chorea-in-huntington-disease-completes-enrollment/2469660/The phase 3 KINECT-HD clinical study (NCT04102579) of valbenazine (Ingrezza; Neurocrine Biosciences, San Diego, CA) for treatment of chorea in Huntington disease (HD) has completed enrollmen
- Flavonoids May Reduce Risk of Subjective Cognitive Declinehttps://practicalneurology.com/news/flavonoids-may-reduce-risk-of-subjective-cognitive-decline/2469656/A study published in Neurology suggests the risk of cognitive decline may be lowered by as much as 20% with a diet rich in flavonoids. Foods that are high in flavonoids include strawberries, oranges, pepp
- Pimavanserin Effective for Dementia-Related Psychosishttps://practicalneurology.com/news/pimavanserin-effective-for-dementia-related-psychosis/2469641/As published in The New England Journal of Medicine, pimavanserin (Acadia Pharmaceuticals; San Diego, CA) treatment made relapse of dementia related psychosis (DRP) almost 3 times less likely. Results of the phase 3 H
- Phase 3 Study of Tolperisone for Muscle Spasms Reaches 50% Enrollmenthttps://practicalneurology.com/news/phase-3-study-of-tolperisone-for-muscle-spasms-reaches-50-enrollment/2469609/For the phase 3 RESUME-1 clinical study (NCT04671082) of tolperisone (Mydocalm; Neurana Pharmaceuticals, San Diego, CA), 500 of the planned 1,000 participants have enrolled. Tolperisone works as a centrally active muscle relaxant for treatment of acute and painful muscles spasms of the back.
- Rimegepant Now Approved for Both Acute and Preventive Migraine Treatmenthttps://practicalneurology.com/news/rimegepant-now-approved-for-both-acute-and-preventive-migraine-treatment/2469603/The FDA has approved rimegepant (Nurtec; Biohaven Pharmaceuticals, New Haven, CT) for the additional indication of preventive treatment of migraine. The approval for preventative migraine treatment makes rimegepant the first drug approved to treat acute migraine attacks and help prevent future mi
- FDA Approves Pimavanserin Administration by Opening Capsule and Sprinkling Onto Food or Into Liquidhttps://practicalneurology.com/news/fda-approves-pimavanserin-administration-by-opening-capsule-and-sprinkling-onto-food-or-into-liquid/2469448/The Food and Drug Administration (FDA) approved a supplement application to update the pimavanserin (Nuplazid; Acadia Pharmaceuticals, San Diego, CA) prescription information. This update provides instructions for sprinkling the contents of pimavanserin capsules on food and liquids for dosing and